Century Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Century Therapeutics develops allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for cancer and other diseases, engineering off-the-shelf natural killer and T-cell products designed for standardized manufacturing and repeat dosing.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Russotti GregorySee Remarks | Sell | $1K | 534at $2.05 | Sep 8, 2026 |
| Carr DouglasSVP Finance & Operations | Sell | $521 | 254at $2.05 | Sep 8, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable IPSC activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.